Is Hub Optimization the Key for Drug Launches?

01/03/24 • 26 min

So you’ve developed a great new specialty drug but will patients and providers utilize your therapy correctly? A great hub can help but implementing one is no easy task.

Justine Hughes, a vice president with Archbow Consulting, joins The IDI to explain where pharma and biotech hubs stumble -- and how they can succeed.

Follow Justine Hughes on LinkedIn.

Follow Valuate on LinkedIn.

Learn more about Valuate.

So you’ve developed a great new specialty drug but will patients and providers utilize your therapy correctly? A great hub can help but implementing one is no easy task.

Justine Hughes, a vice president with Archbow Consulting, joins The IDI to explain where pharma and biotech hubs stumble -- and how they can succeed.

Follow Justine Hughes on LinkedIn.

Follow Valuate on LinkedIn.

Learn more about Valuate.

Previous Episode

Politics and Prescription Drugs: What's Ahead in 2024

The new year will be critical for pharma and market access. The industry will need to turn its attention back to the Inflation Reduction Act as the first 10 drugs are up for negotiation with the feds. Plus, there's the small matter of electing a new President.

Al Jackson joins the IDI to help break down what it all means and where all this activity in Washington is headed. An attorney by training, Al was most recently EVP and head of health and public affairs at Ketchum.

Follow Al Jackson on LinkedIn.

Follow Valuate on LinkedIn.

Learn more about Valuate.

Next Episode

What Do Payers Think About Market Access?

It’s no secret that pharmaceutical manufacturers and payers don’t always see eye to eye.

But in order for pharma market access to do its job it needs to better understand payers -- how they think, what keeps them up at night, and what’s trending.

That’s why Valuate conducted its Second Annual Market Access survey late last year. The goal was to better understand payer perspectives on everything from the Inflation Reduction Act to biosimilars to gold bagging.

Tony Gibson, a Principal with Valuate Health, returns to The IDI to break down the results. You can also contact Tony if you want an exclusive readout of the survey.

Follow Tony on LinkedIn.

Follow Valuate on LinkedIn

Learn more about Valuate.